01.12.2008 FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

18.11.2008 Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient

11.11.2008 Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

10.11.2008 Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

10.11.2008 Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe

07.11.2008 Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008

05.11.2008 Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7

03.11.2008 Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York

03.11.2008 Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer

03.11.2008 Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer